新型CYP11B配体[123/131I]IMAZA作为肾上腺皮质肿瘤诊疗一体化工具:临床前全面表征与首次临床经验
本研究针对肾上腺肿瘤诊疗难题,设计新型IMTO衍生物以克服其快速代谢失活,通过体外细胞实验、小鼠体内生物分布及人组织切片结合特异性评估,筛选出[123/131I]IMAZA。在3例转移性肾上腺癌患者中,[123I]IMAZA显像优于[123I]IMTO,且一例快速进展的肾上腺皮质癌患者接受[131I]IMAZA内照射治疗后获得21个月无进展间期。
要点
- [123/131I]IMAZA在临床前及3例患者中显示优于IMTO的药代动力学与显像特性。
- 一例快速进展的肾上腺皮质癌患者经[131I]IMAZA内照射治疗获得21个月无进展间期。
- IMAZA通过替换不稳定甲酯为羧酸酯或酰胺,提高了代谢稳定性并保持高亲和力。
核心结论
- 新型放射性药物[123/131I]IMAZA具有优于参考化合物IMTO的特性,并在人体中展现出有前景的初步经验。
研究设计与样本
- 临床前研究:设计多种IMTO衍生物,在肾上腺皮质细胞系中测试醛固酮和皮质醇合成抑制,评估放射性标记化合物的稳定性、体外细胞摄取、小鼠体内生物分布及与人肾上腺皮质和非肾上腺皮质组织冰冻切片的结合特异性。
- 首次临床研究:在已知转移性肾上腺癌患者中,使用[123I]IMTO和最 promising 的化合物[123I]IMAZA进行闪烁显像,随后对其中一名患者进行[131I]IMAZA首次内照射治疗。
主要发现
- 鉴定出三种IMTO类似物,对目标酶具有高亲和力结合,代谢稳定性相当或更高,并在体外和体内肾上腺皮质细胞中具有非常高且特异性的蓄积。
- 标记的IMAZA在小鼠和3例患者中均表现出优于IMTO的药代动力学和显像特性。
- [131I]IMAZA内照射治疗使一名治疗前快速进展的肾上腺皮质癌患者获得了21个月的无进展间期。
临床怎么用
- 对于肾上腺皮质肿瘤患者,[123I]IMAZA可用于显像评估,[131I]IMAZA可作为潜在的内照射治疗选择。
局限性
- 首次临床经验仅基于3例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adrenal tumors represent a diagnostic and therapeutic challenge. Promising results have been obtained through targeting the cytochrome P450 enzymes CYP11B1 and CYP11B2 for molecular imaging, and [123/131I]iodometomidate ([123/131I]IMTO) has even been successfully introduced as a theranostic agent. As this radiopharmaceutical shows rapid metabolic inactivation, we aimed at developing new improved tracers. METHODS: Several IMTO derivatives were newly designed by replacing the unstable methyl ester by different carboxylic esters or amides. The inhibition of aldosterone and cortisol synthesis was tested in different adrenocortical cell lines. The corresponding radiolabeled compounds were assessed regarding their stability, in vitro cell uptake, in vivo biodistribution in mice, and their binding specificity to cryosections of human adrenocortical and non-adrenocortical tissue. Furthermore, a first investigation was performed in patients with known metastatic adrenal cancer using both [123I]IMTO and the most promising compound (R)-1-[1-(4-[123I]iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinylamide ([123I]IMAZA) for scintigraphy. Subsequently, a first endoradiotherapy with [131I]IMAZA in one of these patients was performed. RESULTS: We identified three analogues to IMTO with high-affinity binding to the target enzymes and comparable or higher metabolic stability and very high and specific accumulation in adrenocortical cells in vitro and in vivo. Labeled IMAZA exhibited superior pharmacokinetic and imaging properties compared to IMTO in mice and 3 patients, too. An endoradiotherapy with [131I]IMAZA induced a 21-month progression-free interval in a patient with rapidly progressing ACC prior this therapy. CONCLUSION: We developed the new radiopharmaceutical [123/131I]IMAZA with superior properties compared to the reference compound IMTO and promising first experiences in humans.
引用
- Heinze B, Schirbel A, Nannen L, et al. Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. Eur J Nucl Med Mol Imaging. 2021. PMID: 34215922. doi:10.1007/s00259-021-05477-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。